New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Key Takeaways

• The proposal aims to expand Medicare and Medicaid coverage to include anti-obesity medications, recognizing obesity as a disease.
• Anti-obesity medications have demonstrated safety and efficacy, but current legislation restricts Medicare Part D coverage.
• If approved, the proposal could benefit millions of patients but would significantly increase Medicare and Medicaid spending.
• The financial impact of the proposal is substantial, with projected costs of $25 billion for Medicare and $11 billion for Medicaid.

If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs starting in 2026.

Today's Sponsors

Today's Sponsor